Chiasma, Inc. (NASDAQ:CHMA) has been assigned an average broker rating score of 5.00 (Strong Sell) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong sell rating.
Brokers have set a 12 month consensus price target of $2.50 for the company, according to Zacks. Zacks has also assigned Chiasma an industry rank of 111 out of 265 based on the ratings given to its competitors.
Separately, ValuEngine raised Chiasma from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
In related news, Director Scott Minick purchased 15,000 shares of the stock in a transaction dated Wednesday, September 20th. The stock was bought at an average cost of $2.38 per share, with a total value of $35,700.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 3.80% of the company’s stock.
An institutional investor recently bought a new position in Chiasma stock. Dimensional Fund Advisors LP purchased a new stake in Chiasma, Inc. (NASDAQ:CHMA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 53,481 shares of the biotechnology company’s stock, valued at approximately $136,000. Dimensional Fund Advisors LP owned about 0.22% of Chiasma at the end of the most recent reporting period. Hedge funds and other institutional investors own 54.56% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/16/chiasma-inc-chma-receives-average-recommendation-of-strong-sell-from-analysts.html.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.